NKore BioTherapeutics Held FDA Pre-IND Meeting
Los Angeles-based NKore BioTherapeutics completed a key regulatory meeting for its cancer therapy candidate NK101.
Live Poll
Do you trust that private biotechnology firms will prioritize patient safety in their cancer therapy development?